Company Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.
The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,300 |
| CEO | Thomas Appio |
Contact Details
Address: 2150 St. Elzéar Blvd. West Laval, QC H7L 4A8 Canada | |
| Phone | 514 744 6792 |
| Website | bauschhealth.com |
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer and Director |
| Jean-Jacques Charhon | Executive Vice President and Chief Financial Officer |
| Seana Carson | Executive Vice President and General Counsel |
| Aimee J. Lenar | Executive Vice President of US Pharma |
| Mirza Dautbegovic | Executive Vice President and Chief Operating Officer |
| Steven H. Lee | Senior Vice President, Controller and Chief Accounting Officer |
| Garen Sarafian | Vice President and Head of Investor Relations |
| Kathleen Fitzpatrick | Executive Vice President and Chief Human Resources and Communications Officer |
| Cees Heiman | Senior Vice President of Europe and Canada |
| Jiny Kim M.B.A. | Senior Vice President of Solta Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2026 | ARS | Filing |
| Apr 8, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 19, 2026 | 10-K | Annual Report |
| Feb 18, 2026 | 8-K | Current Report |
| Jan 23, 2026 | 8-K | Current Report |